Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...

Texas Attorney General Ken Paxton has filed a lawsuit in state court against Eli Lilly and Co., accusing the pharmaceutical ...

Texas is seeking more than $1 million from Eli Lilly in a lawsuit accusing the drugmaker of persuading physicians to prescribe its medications, including GLP-1s such as Mounjaro and Zepbound, through ...

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

Attorney General Ken Paxton filed a lawsuit this week against Eli Lilly for allegedly bribing Texas health care providers to ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

More than 1 in 4 adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the ...

Novo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.